Teva Shares Rally on Opioid Settlement, but Analysts Have Doubts

Tentative $23 billion deal announced on Monday could be boost for financially troubled Israeli drug maker. But deal remains short on details, and not all the plaintiffs may sign on

Send in e-mailSend in e-mail
The logo for Teva appears above a trading post on the floor of the New York Stock Exchange, October 21, 2019.
The logo for Teva appears above a trading post on the floor of the New York Stock Exchange, October 21, 2019. Credit: Richard Drew,AP

Comments